NMTC

NEUROONE MEDICAL TECHNOLOGIES Corp

Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001500198 Healthcare & Medical Devices

$0.8285 +0.02 (+3.05%)

Oct 27 4:00 PM ET · prev $0.8040

Market cap

$8.4M

Nano cap

Consensus

Buy

89% Buy or better · 9 analysts

Median target

$8.00

+866% · range $5.00–8.80

1 year

−83.5%

from $5.01 · Oct 27

30 days

−36.3%

from $1.30

52-week range

$0.8040–5.89

−86% from high · low Oct 26

Avg volume 20D

161.1K

Oct 5 spike 1.00M

Short interest

🔒 Subscribers only

Insider net

+$682.5K

1 buyer · 1 seller · 12 mo

Filing reports

analyzed by SecBot

SecBot read BULLISH 4 reports · 90 days

Balance 0 bearish · 2 bullish · 2 mixed oldest → newest, height = score

Avg score

Strongest BULLISH NeuroOne reported preliminary Q4 FY2026 product revenue of ~$3.8M (+38.4% YoY) and full-year revenue of…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

B Mar 1 1 insider buy $670.4K at $0.6704
S Mar 10 to Mar 13 4 days of insider sells: $11.7K by 1 insider, avg $0.8000
S Mar 30 1 insider sell $11.4K at $0.7400
S Jun 30 1 insider sell $31.8K at $3.18
B Aug 27 1 insider buy $67.0K at $2.01
E Aug 27 Trading halt: Halt Resumed: NMTC — trading resumed after LUDP (Volatilit…
X Sep 30 Short interest jumps 135.8% to 178.7K
R Oct 5 NeuroOne reported preliminary Q4 FY2026 product revenue of ~$3.8M (+…

Signal stack

Where each data set points today.

InsidersBULLISH

1 insider bought $737.4K. 1 insider sold $54.9K.
AnalystsBULLISH

8 of 9 rate it Buy or better. Every target is above the price.
EstimatesFLAT

Current-quarter EPS estimate −$0.190 → −$0.193 over 90 days. 0 up, 2 down in 30 days.
TrendDOWNTREND

40% below its 50-day average. New closing low $0.8040 on Oct 26.
SocialQUIET

No Reddit mentions this week. Last mention Oct 9.

Who's buying

13F

Top holder	Shares	Value
VANGUARD CAPITAL MANAGEMENT LLC	352,774	$1.1M
GEODE CAPITAL MANAGEMENT, LLC	93,555	$284.4K
RENAISSANCE TECHNOLOGIES LLC	70,861	$215.4K
VANGUARD FIDUCIARY TRUST CO	49,018	$149.0K
BlackRock, Inc.	25,121	$76.4K
NORTHERN TRUST CORP	21,398	$65.0K
CITADEL ADVISORS LLC	15,032	$45.7K
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13,520	$41.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts

Buy 89% rate it Buy or better

Strong Buy3Buy5Hold1Sell0Strong Sell0

12-month targets · 3 analysts

$0.8285 $5.00 $8.00 $8.80

Price is below the lowest target. Median implies +866%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Aug 14, 2026	Maxim Group MAINTAIN	MAINTAIN	Buy
May 13, 2026	Ladenburg Thalmann MAINTAIN	MAINTAIN	Buy

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Oct 22, 2026 Other

NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program

NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform

Oct 5, 2026 SEC

NeuroOne reported preliminary Q4 FY2026 product revenue of ~$3.8M (+38.4% YoY) and full-year revenue of ~$10.5M…

8-K — Impact 6/10

Oct 5, 2026 SEC

NeuroOne reported preliminary Q4 FY2026 product revenue of $3.8M (+38.4% YoY) and full-year revenue of $10.5M (+15.6%…

PRESS-RELEASE — Impact 5/10

Aug 28, 2026 Insider

Wambeke David J. was granted 35,000 shares

Chief Business Officer

Aug 28, 2026 Insider

Johns Emily J. was granted 12,500 shares

Chief Administrative Officer

Aug 28, 2026 Insider

Volker Christopher was granted 35,000 shares

Chief Financial Officer

Aug 27, 2026 SEC

NeuroOne Medical Technologies (NMTC) announced successful completion of three large-animal procedures using its…

8-K — Impact 5/10

Insider ledger

Form 4

$737.4K

bought · 1 insider

$54.9K

sold · 1 insider

Date	Insider	Type	Value
Aug 28, 2026	Wambeke David J. Chief Business Officer	AWARD	35,000 sh
Aug 28, 2026	Johns Emily J. Chief Administrative Officer	AWARD	12,500 sh
Aug 28, 2026	Volker Christopher Chief Financial Officer	AWARD	35,000 sh
Aug 28, 2026	Mertens Steve Chief Technology Officer	AWARD	15,000 sh
Aug 28, 2026	Christianson Mark Market Development Director	AWARD	12,500 sh
Aug 28, 2026	Rosa David A CEO & President	AWARD	68,000 sh
Aug 27, 2026	Wambeke David J. Chief Business Officer	BUY	$67.0K
Jun 30, 2026	Christianson Mark Market Development Director	SELL	$31.8K

Earnings setup

Estimates

−$0.19

EPS estimate, this quarter

−2%

estimate change, 90 days

0↑ 2↓

revisions, 30 days

Current-quarter EPS estimate

−$0.190

90d

−$0.190

60d

−$0.217

30d

−$0.217

−$0.193

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.19	-$0.20–-$0.19	+10.8%	$3.8M
Next Q	-$0.17	-$0.22–-$0.14	+0.0%	$3.3M
Current FY	-$0.71	-$0.88–-$0.39	+3.2%	$10.5M
Next FY	-$0.63	-$0.78–-$0.41	+0.0%	$13.3M

Short side

FINRA· Oct 15, 2026

🔒 Subscribers only

shares short

Trading halts

Aug 27, 2026

Volatility Pause

Resumed

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Recent

Oct 22, 2026

Press release

NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program

NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical…

Oct 5, 2026

Earnings

NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

Sep 17, 2026

Press release

NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement

Aug 27, 2026

Trading halt

Halt Resumed: NMTC — trading resumed after LUDP (Volatility Trading Pause)

Halted 2026-08-27T13:34:07.000Z | Resumed 2026-08-27T13:44:07.000Z

Aug 27, 2026